What are the pharmacotherapy options for hyperlipidemia?

Pharmacotherapy Options for Hyperlipidemia

Statins are the cornerstone of lipid-lowering therapy and should be initiated as first-line pharmacotherapy for hyperlipidemia, with intensity selected based on cardiovascular risk and target LDL-C reduction. 1

First-Line Therapy: Statins

Statins remain the primary pharmacologic intervention for hyperlipidemia management, categorized by intensity of LDL-C lowering 1:

• High-intensity statins (≥50% LDL-C reduction): Atorvastatin 40-80 mg or rosuvastatin 20-40 mg
• Moderate-intensity statins (30-49% LDL-C reduction): Atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, lovastatin 40 mg, fluvastatin 80 mg, pitavastatin 1-4 mg
• Low-intensity statins (<30% LDL-C reduction): Simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, fluvastatin 20-40 mg

Statin Selection Algorithm

For secondary prevention (established ASCVD) in patients ≤75 years: Initiate high-intensity statin therapy targeting ≥50% LDL-C reduction 1. If high-intensity statins are contraindicated or cause side effects, use moderate-intensity statins targeting 30-49% reduction 1.

For primary prevention: Base intensity on 10-year ASCVD risk calculation and individual risk factors 1.

Second-Line Add-On Therapies

Ezetimibe

When statins alone are insufficient, add ezetimibe before considering more expensive options. 2

• Mechanism: Inhibits intestinal cholesterol absorption
• LDL-C reduction: 18% as monotherapy; additional 25% when combined with statins 2
• Evidence: IMPROVE-IT trial demonstrated cardiovascular benefit when added to moderate-intensity statins in post-ACS patients; SHARP trial showed benefit in chronic kidney disease 2
• Dosing: 10 mg daily, with or without food
• Key advantage: Generally well-tolerated, generic available, minimal drug interactions 2

PCSK9 Inhibitors (Alirocumab, Evolocumab)

For very high-risk ASCVD patients on maximally tolerated statin plus ezetimibe with LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL, adding a PCSK9 inhibitor is reasonable after discussing net benefit, safety, and cost. 1

• Mechanism: Monoclonal antibodies that bind PCSK9, increasing LDL receptor availability 2
• LDL-C reduction: >50% beyond statin-treated baseline 3
• Dosing:
  • Alirocumab: 75-150 mg SC every 2 weeks or 300 mg every 4 weeks 2
  • Evolocumab: 140 mg SC every 2 weeks or 420 mg monthly 2
• Evidence: Large outcomes trials demonstrated cardiovascular event reduction 2, 3
• Limitation: High cost; reserve for patients who truly need additional LDL-C lowering 1

Emerging and Alternative Therapies

Bempedoic Acid

• Mechanism: Inhibits ATP citrate lyase in hepatic cholesterol synthesis 4, 3
• Key advantage: Does not cause muscle-related adverse events, making it suitable for statin-intolerant patients 5
• LDL-C reduction: Significant reduction without myopathy risk 4

Inclisiran

• Mechanism: Small interfering RNA (siRNA) targeting PCSK9 production 4, 3
• Key advantage: Prolonged dosing intervals (twice yearly after loading doses) 4
• Status: Represents newer siRNA technology with promising efficacy 5

Bile Acid Sequestrants

• Agents: Cholestyramine, colesevelam, colestipol
• Evidence: Reduce cardiovascular events 6
• Limitation: Gastrointestinal side effects limit tolerability; must dose ezetimibe 2 hours before or 4 hours after if combined 2

Therapies with Limited or No Cardiovascular Benefit

Fibrates and Niacin

Do not add fibrates or niacin to statin therapy for cardiovascular risk reduction. 1

• Randomized controlled trials do not support their use as add-on drugs to statins 1
• Fibrates have mild LDL-lowering action but lack outcome benefit when combined with statins 6
• Consider fibrates primarily for severe hypertriglyceridemia (>500 mg/dL) to prevent pancreatitis, not for ASCVD risk reduction

Special Populations

Familial Hypercholesterolemia (Homozygous)

For refractory cases, additional options include:

• Lomitapide: Microsomal triglyceride transfer protein inhibitor 7
• Mipomersen: Antisense oligonucleotide targeting apoB-100 7
• LDL apheresis: For severe cases unresponsive to pharmacotherapy 7

Hypertriglyceridemia

• Volanesorsen: siRNA targeting apolipoprotein C-III 4
• Omega-3 fatty acids: Consider for triglyceride lowering, though cardiovascular benefit is debated

Critical Pitfalls to Avoid

1. Do not use fibrates or niacin as add-on therapy to statins for ASCVD prevention - no outcome benefit demonstrated 1
2. Do not jump to PCSK9 inhibitors without maximizing statin and ezetimibe first - cost-effectiveness requires appropriate patient selection 1
3. Do not abandon statins prematurely for muscle symptoms - many patients can tolerate alternative statins or lower doses 1
4. Do not forget to measure fasting lipids when triglycerides ≥400 mg/dL on initial nonfasting panel 1

Treatment Sequencing Algorithm

1. Start: High or moderate-intensity statin based on ASCVD risk
2. If inadequate response: Add ezetimibe
3. If still inadequate in very high-risk patients: Consider PCSK9 inhibitor
4. If statin-intolerant: Try alternative statin, lower dose, or consider bempedoic acid
5. Reserve specialized therapies (lomitapide, mipomersen, apheresis) for familial hypercholesterolemia

This algorithmic approach prioritizes evidence-based therapies with proven cardiovascular outcomes while avoiding medications that lower lipids without improving morbidity or mortality 1, 2.